Jürgen Rawert

Title: Jürgen Rawert: Innovator in Prostate Treatment

Introduction

Jürgen Rawert is a notable inventor based in Alzenau, Germany. He has made significant contributions to the field of medical treatment, particularly concerning prostate health. His innovative approach has led to the development of a unique therapeutic regime aimed at managing benign prostatic hyperplasia and prostate cancer.

Latest Patents

Jürgen Rawert holds a patent for a method titled "Means for treating prostate hypertrophy and prostate cancer." This patent outlines a regime that employs Cetrorelix, either alone or in combination with alpha-reductase inhibitors or alpha-receptor blocking agents. The treatment is designed to reduce prostate volume while minimizing the side effects associated with testosterone levels being in a castration range. Cetrorelix is administered in varying dosages, ranging from 0.5 mg/day to 20 mg/week, or approximately 0.014 mg/kg body weight per day to 0.30 mg/kg body weight per week. The regimen can also include dosages of about 25 to 120 mg of Cetrorelix per month.

Career Highlights

Jürgen Rawert is associated with Asta Medica, Aktiengesellschaft, where he has been instrumental in advancing medical treatments. His work has not only contributed to the scientific community but has also provided new hope for patients suffering from prostate-related conditions. His innovative methods have garnered attention for their effectiveness and potential impact on patient care.

Collaborations

Some of Jürgen Rawert's notable coworkers include Jürgen Engel and Thomas Reissmann. Their collaborative efforts have further enhanced the research and development of effective treatments in the medical field.

Conclusion

Jürgen Rawert's contributions to the treatment of prostate conditions exemplify the importance of innovation in medicine. His patented methods represent a significant advancement in therapeutic management, showcasing the potential for improved patient outcomes.